NWBO: Northwest Biotherapeutics, Inc. Market Currents

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, April 18, 10:36 AM Northwest Biotherapeutics (NWBO -4.2%) falls hard after announcing a $10M direct placement (price is $3.90) with "one healthcare-dedicated institutional investor" who also received warrant coverage of 40% (exercise price $4.29) for a term of five years. 6 Comments [On the Move, Healthcare]
Tuesday, April 16, 10:30 AM Northwest Biotherapeutics (NWBO +5.7%) racks up a solid gain this morning after saying that it's Phase III clinical trial for Glioblastoma multiforme brain cancer has been adopted as a national priority trial in the UK. The development was under the "adoption" program managed by the National Institute for Health Research, which is part of the UK's National Health System, and with it comes resources and operational support for the trial sites. Comment! [Healthcare, Global & FX, On the Move]
Tuesday, April 16, 9:10 AM Premarket gainers: NWBO +9%. GFI +7%. BCRX +7%. HK +7%. AU +7%. NG +6%. AUQ +6%. SAND +6%. GOLD +5%. KGC +5%.
Losers: LDK -16%. SRPT -11%. 1 Comment [On the Move]
Monday, March 18, 10:23 AM Northwest Biotherapeutics (NWBO +7%) trades up this morning after being issued a patent by the USPTO covering processes for manufacturing human dendritic cells. The process focuses on producing pure dendritic cells, which are much more potent in their capacity to activate the immune system than those produced by the standard methods used throughout academia and industry today. Comment! [Healthcare, On the Move]
Thursday, March 7, 8:30 AM Northwest Biotherapeutics (NWBO +2%) expects to complete the enrollment of a 312-patient Phase III trial for its Glioblastoma multiforme brain cancer drug by Q1 or early Q2 next year. NW Bio says its recruitment is faster or more efficient than that for rival drugs, including for treatments from Celldex (CLDX), Immunocellular (IMUC) and Agenus (AGEN). (PR) 1 Comment [Healthcare]
Wednesday, November 21, 2012, 10:09 AM SA author Austrolib provides a run-through of cancer vaccines from the "underwhelming to the exciting." The latter includes OncoVEX from Amgen (AMGN), which would be a buy if it weren't "skirting its all-time highs of $89 a share." Even more interesting are DCVax-L (brain) and DCVax-Direct (inoperable tumors) from Northwest Biotherapeutics (NWBO.OB). The problem is that Northwest has little cash and lots of debt notes. Comment! [Healthcare, Quick Ideas]

NWBO Northwest Biotherapeutics, Inc.

NWBO

Northwest Biotherapeutics, Inc.